AMD (age-related macular degeneration) treatment coverage on the agenda at US MCAC (Medicare Coverage Advisory Committee)
This article was originally published in Clinica
Executive Summary
US Medicare has scheduled a meeting of its private sector Medicare Coverage Advisory Committee (MCAC) on November 29 to discuss treatments for age-related macular degeneration (AMD), the leading cause of legal blindness in people over the age of 50.